SHH · 688076.SS
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.
CN¥27.05+CN¥0.03 (+0.11%)
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 34.3% below the high.
Loading market information…
SHH · 688366.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:14 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Shanghai Haohai Biological Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Shanghai Haohai Biological Technology Co., Ltd.’s forward annual dividend is CN¥0.50 per share, paid semi-annual. The forward yield is 1.72% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Shanghai Haohai Biological Technology Co., Ltd.’s next earnings report is currently expected on Mar 22, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shanghai Haohai Biological Technology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and distribution of advanced biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various international markets. The company's extensive product portfolio serves multiple medical fields. For ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, specialized orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. In orthopedics, they provide sodium hyaluronate injections and medical chitosan. Their wound care segment features recombinant human epidermal growth factor, effective in treating a broad spectrum of injuries, including burns, residual wounds, donor site trauma, post-traumatic wounds, and both acute and chronic ulcerations. Anti-adhesion solutions are offered in the form of medical sodium hyaluronate gel and medical chitosan, while hemostatic products include collagen sponges and porcine fibrin sealants. Within medical aesthetics, Shanghai Haohai produces a diverse range of hyaluronic acid (HA) dermal fillers: Matrifill, a first-generation mono-phase injectable gel; Janlane, a second-generation filler engineered for dynamic applications; and Hyalumatrix, a third-generation product designed for precise aesthetic enhancements. This division also supplies radio frequency devices and laser equipment. Beyond its core product offerings, the company actively pursues research and development in biological engineering and pharmaceutical innovations. It also provides related technology transfer and consultation services, alongside engaging in investment and trading activities. Originally established in 2007 as Haohai Limited, the company adopted its current name, Shanghai Haohai Biological Technology Co., Ltd., in 2010 and is headquartered in Shanghai, China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥617.29M |
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥27.05+CN¥0.03 (+0.11%)
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 34.3% below the high.
CN¥5.00-CN¥0.05 (-0.99%)
Chengzhi Shareholding Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.86% below the high.
CN¥12.03+CN¥0.03 (+0.25%)
Zhejiang Jolly Pharmaceutical Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 35.5% below the high.
CN¥14.98+CN¥1.36 (+9.99%)
Guilin Sanjin Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.89% below the high.
CN¥18.40+CN¥0.25 (+1.38%)
Aurisco Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.29% below the high.
CN¥41.63-CN¥0.14 (-0.34%)
Chengdu Easton Biopharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.27% below the high.
CN¥13.71-CN¥0.16 (-1.15%)
China Resources Boya Bio-pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.53% below the high.
CN¥4.10+CN¥0.01 (+0.24%)
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong’s quoted price sits in the lower half of its reported 52-week range, 50.36% below the high.
